PBYI Puma Biotechnology Inc

40.10
-1  -3%
Previous Close 41.55
Open 41.50
Price To book 7.29
Market Cap 1.48B
Shares 36,951,000
Volume 374,813
Short Ratio 9.04
Av. Daily Volume 982,347

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Note this trial is conducted by competitor Roche (RHHBY), NOT by Puma. The event was likely to have a significant impact on the share price of Puma (e.g. positive data would likely have a negative impact on Puma and vice versa). Data were released March 2, 2017 - primary endpoint was met.
Roche (RHHBY) - Perjeta + Herceptin (APHINITY)
Adjuvant HER2+ breast cancer
Phase 2 data due 2Q 2017.
Neratinib
HER2-positive metastatic breast cancer patients with brain metastases
Phase 3 planned
Neratinib plus temsirolimus
Fourth line HER2-positive metastatic breast cancer
Phase 2 biomarker data released December 7, 2016. Further interim data due 2Q 2017.
PB272 (NSABP FB-7)
Neoadjuvant treatment for patients with HER2-positive breast cancer
Phase 2 preliminary data released December 8, 2016. Further data due 2Q 2017.
Neratinib SUMMIT
HER2 non-amplified breast cancer that has a HER2 mutation
Phase 2 additional data released December 8 2016. Noted high rates of diarrhea. Further data due 2Q 2017.
Neratinib monotherapy with high dose loperamide prophylaxis - CONTROL
Extended adjuvant treatment of early stage HER2-positive breast cancer
Phase 3 data due 1H 2017.
Neratinib
Third-line HER2-positive metastatic breast cancer
Phase 2 completed.
Neratinib - NEfERTT trial
HER2-positive breast cancer first line
Announced acceptance of NDA Filing September 20, 2016. PDUFA estimate July 20, 2017.
PB272 ExteNET trial
Extended adjuvant HER2-positive early stage breast cancer

Latest News

  1. PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and
  2. Finding Bullish and Bearish Market Reversals
  3. 7 Stocks Trending Up With Monster Volume
  4. Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High
  5. PUMA BIOTECHNOLOGY, INC. Financials
  6. Kroger, Shake Shack and Puma dip; Monster Beverage gains
  7. Kroger, Shake Shack and Puma dip; Monster Beverage gains
  8. Puma (PBYI) Q4 Loss Wider than Expected, Neratinib in Focus
  9. Why Puma Biotechnology Inc. Got Hammered Today
  10. Puma Biotechnology to Present at Cowen’s Health Care Conference
  11. Puma Plunges on Breast Cancer Drug Update
  12. Top Biotech Stocks With FDA Decisions in 2017
  13. Puma Biotech shares plummet 26% after Roche reports positive results for late-stage breast cancer drug
  14. Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win
  15. Puma Biotech reports 4Q loss
  16. Puma Biotech reports 4Q loss
  17. Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017
  18. PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  19. Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272
  20. Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272